aggrecan neoepitope antibody - bsa free  (Bio-Techne corporation)

Journal: Bone Research

Article Title: Cytosolic phospholipase A2 as a therapeutic target for degenerative joint diseases

doi: 10.1038/s41413-025-00470-9

Figure Lengend Snippet: Deletion of cPLA2 protects against surgically-induced OA. a Representative Safranin O/Fast Green stained images of knee joints from WT and cPLA2 KO male mice ( n = 7) at 12 weeks after DMM or sham surgery. Scale bar = 100 μm. b , c 2 min travel distance ( b ) and von Frey pain assay ( c ) in WT and cPLA2 KO mice at the indicated time after DMM surgery ( n = 7). d Representative immunohistochemical staining images of cPLA2, Col2, Mmp13, aggrecan neoepitope, p16, and p21 in knee joint sections from each group ( n = 7). Scale bar = 50 μm. e 3D micro-CT images of pathological changes in mouse knee joints 12 weeks post-surgery ( n = 4). f 3D micro-CT images of osteophyte formation, calcified meniscus and synovial tissue, with red-marked regions indicating osteophytes ( n = 4). g Quantification of osteophyte number (Op.N, I), size (Op.TV, J), and the volume of calcified meniscus and synovial tissue (Cal Tis.V, K). g Data are mean±s.d., P -values by two-tailed unpaired Student’s t -test

Article Snippet: Sections were incubated overnight at 4 °C with primary antibodies against Col II (ProteinTech, Cat. 28459-1-AP), aggrecan neoepitope (Novus Biologicals, Cat. NB100-74350), MMP13 (ProteinTech, Cat. 18165-1-AP), cPLA2 (CST, Cat. 2831), p16 (CST, Cat. 18769), and p21 (Invitrogen, Cat. MA5-14949).

Techniques: Staining, Immunohistochemical staining, Micro-CT, Two Tailed Test

Journal: Bone Research

Article Title: Cytosolic phospholipase A2 as a therapeutic target for degenerative joint diseases

doi: 10.1038/s41413-025-00470-9

Figure Lengend Snippet: cPLA2 inhibition protects against OA in a surgically induced model. a Schematic of the experimental outline. 12-week-old male WT mice underwent DMM or sham surgery. Starting at 4 weeks post-surgery, the mice were treated daily with either 10 mg/kg body weight FFD or 10 mg/kg body weight AACOCF3 for a duration of eight weeks ( n = 6). b Representative Safranin O/Fast Green stained images of knee joints treated with/without FFD or AACOCF3 at 12 weeks post-surgery ( n = 6). Scale bar = 100 μm. c , d 2 min travel distance ( c ) and von Frey pain assay ( d ) in mice with varying treatment at the indicated time points after surgery ( n = 6). e Representative immunohistochemical staining images of p -cPLA2, cPLA2, Col2, Mmp13, aggrecan neoepitope, p16, and p21 in knee joint sections from each group ( n = 6). Scale bar = 50 μm. f Quantification of positive staining based on IHC images in ( e ) ( n = 6). c , d , f Data are mean±s.d., P -values by one way ANOVA with Bonferroni post hoc test. *, P < 0.05, **, P < 0.001, *** P < 0.001

Article Snippet: Sections were incubated overnight at 4 °C with primary antibodies against Col II (ProteinTech, Cat. 28459-1-AP), aggrecan neoepitope (Novus Biologicals, Cat. NB100-74350), MMP13 (ProteinTech, Cat. 18165-1-AP), cPLA2 (CST, Cat. 2831), p16 (CST, Cat. 18769), and p21 (Invitrogen, Cat. MA5-14949).

Techniques: Inhibition, Staining, Immunohistochemical staining